研究者主導臨床試験に望まれる安全性情報の取扱いについて

Yuka Takao, Chiho Tsunoda, Maki Kimura, Koji Todaka

研究成果: ジャーナルへの寄稿学術誌査読

抄録

Timely reporting and appropriate response to safety information related to ongoing clinical trials is crucial for conducting trials appropriately and safely. However, it is difficult to understand exactly what, when, and to whom information should be reported because there are different types of clinical trials in Japan, governed by different laws and regulations. For example, principal investigators need to report serious, unrelated adverse events in "Chiken"clinical trials, but not in clinical trials specified under the Clinical Trials Act 2017. This paper clarifies the principal investigator's responsibility for reporting under the three laws related to clinical trials: the Pharmaceuticals and Medical Devices Act, the Clinical Trials Act, and the Act on the Safety of Regenerative Medicine. Report items were explained and summarized in a table. The paper also separately covers trials under other frameworks, such as the Ethical Guidelines for Medical and Health Research Involving Human Subjects. The paper will therefore help principal investigators to better understand their responsibilities and manage safety information in clinical trials under various frameworks in Japan. The paper also discusses some current issues that still need resolving.

寄稿の翻訳タイトルSafety information management in investigator-initiated trials in Japan
本文言語日本語
ページ(範囲)13-19
ページ数7
ジャーナルJapanese Journal of Clinical Pharmacology and Therapeutics
52
1
DOI
出版ステータス出版済み - 2021

!!!All Science Journal Classification (ASJC) codes

  • 薬理学
  • 薬理学(医学)

フィンガープリント

「研究者主導臨床試験に望まれる安全性情報の取扱いについて」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル